切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2020, Vol. 10 ›› Issue (05) : 286 -291. doi: 10.3877/cma.j.issn.2095-1221.2020.05.006

所属专题： 文献；

综述

白细胞介素-10在移植物抗宿主病中的研究进展
洪雅群1, 李晓帆1,†()   
  1. 1. 350001　福州，福建医科大学附属协和医院血液科　福建省血液病研究所　福建省血液病学重点实验室　福建医科大学附属协和医院造血干细胞移植中心　福建医科大学血液病学转化医学中心
  • 收稿日期:2020-01-29 出版日期:2020-10-01
  • 通信作者: 李晓帆
  • 基金资助:
    国家自然科学基金(81200400); 福建省青年拔尖创新人才(2017JL-001); 福建省杰出青年科研人才培育计划(JA14130); 福建省杰青科学基金(2016J06018); 福建省科技创新联合资金项目(2016Y9025); 福建医科大学高等教育教学改革工程项目(Y17005)

Advances of interlukin-10 in graft versus host disease

Yaqun Hong1, Xiaofan Li1,†()   

  1. 1. Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou 350000, China
  • Received:2020-01-29 Published:2020-10-01
  • Corresponding author: Xiaofan Li
  • About author:
    Corresponding author: Li Xiaofan, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

洪雅群, 李晓帆. 白细胞介素-10在移植物抗宿主病中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(05): 286-291.

Yaqun Hong, Xiaofan Li. Advances of interlukin-10 in graft versus host disease[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(05): 286-291.

移植物抗宿主病（GVHD）是异基因造血干细胞移植主要的并发症之一，是移植后非复发死亡的重要原因之一。近年来，对GVHD发病机制的研究取得了一些进展。免疫细胞及细胞因子网络在GVHD的发生发展中发挥着重要作用，其中白细胞介素-10（IL-10）在GVHD中的作用已被多次报道，有望成为GVHD潜在的治疗靶点。本综述整理最近在GVHD领域与IL-10相关的文献，总结了IL-10与GVHD发生发展的相关性及治疗研究进展，分列了不同来源的IL-10在GVHD中的作用及潜在的相关临床防治前景。

关键词: 移植物抗宿主病, 白细胞介素-10, 异基因造血干细胞移植

Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic stem cell transplantation, and also one of the leading causes of non-relapse mortality after transplantation. During the past decades, a great progress has been made in the pathophysiology of GVHD. Immune cells and the cytokine network have been demonstrated to contribute to the development of GVHD. Particularly, it is reported that interleukin-10 plays an important role in GVHD. Therapies targeting interleukin-10 have been reported as well. This review focuses on the role of interleukin-10 in GVHD. Therapeutic potential of interleukin-10 in the treatment of GVHD are also discussed.

Key words: Graft versus host disease, Interleukin-10, Allogeneic hematopoietic stem cell transplantation
表1 IL-10与GVHD相关性研究
文献（第一作者） GVHD分型 研究方法 结果
Lin[6] 急性GVHD 遗传学分析 供者IL-10受体相关IL10RB/c238基因型的表达、低转录IL-10 mRNA的IL-10/-592 A/C or A/A基因型与急性GVHD严重程度负相关
Karabon[7] 急性GVHD 遗传学分析 受者高分泌型IL-10 GCC/GCC基因型和供者IL-10低分泌型IL-10 ACC基因型与急性GVHD发生及严重程度负相关
Noori-Daloii[8] 急性GVHD 遗传学分析 受者低分泌型IL-10/CAA基因型与急性GVHD发生负相关
Granero Farias[9] 急性GVHD 遗传学分析 受者IL-10-1082 GG基因型与急性GVHD发生正相关
Cavet[10] 急性GVHD 遗传学分析 受者IL-10-1064基因型与急性GVHD严重程度正相关
蔡小矜[11] 急性GVHD 遗传学分析 受者低分泌型受者IL-10 ATA/ATA基因型与急性GVHD发生负相关
林嘉衍[121] 儿童急性GVHD 遗传学分析 受者IL-10基因一592（C→A）位点AA基因型低分泌型与急性GVHD发生负相关
Goussetis[13] 儿童急性GVHD 遗传学分析 高分泌型IL-10 GCC单倍型与重度急性GVHD的发生负相关
Takahashi[14] 慢性GVHD 遗传学分析 IL-10相关等位基因数增加与慢性GVHD正相关
Kim[15] 慢性GVHD 遗传学分析 IL-10启动子基因多态性与慢性GVHD发生率相关，在ACC/ACC、ATA/ACC、ATA/ATA单倍型中的相关性分别为43﹪、68﹪、96﹪，ATA/ACC、ATA/ATA均为低分泌型
Miura[16] 自体GVHD （自体造血干细胞移植患者）遗传学分析 高分泌IL-10的IL-10?1082 G/G多态等位基因的表达与GVHD发生正相关
Hueso[17] 急性GVHD 患者外周血IL-10水平检测 IL-10 ≥ 90 pg/mL与急性GVHD发展正相关
Sakata[18] 急性GVHD 患者外周血IL-10水平检测 IL-10水平与急性GVHD严重程度正相关
Ju[19] 急性GVHD 患者外周血IL-10水平及IL-10 mRNA水平检测 IL-10蛋白及IL-10 mRNA水平与急性GVHD的发生负相关
Ju[20] 急性GVHD 患者外周血IL-10水平检测 IL-10水平与急性GVHD发生负相关
Fujii[21] 急性GVHD 患者外周血IL-10水平检测 IL-10水平与急性GVHD发生正相关
Remberger[22] 急性GVHD 患者外周血IL-10水平检测 IL-10水平与GVHD进展正相关
Weston[23] 急性GVHD 患者外周血单个核细胞分析 产IL-10细胞数与急性GVHD的严重程度负相关
K?rholz[24] 慢性GVHD 患者外周血IL-10水平检测 IL-10水平与慢性GVHD负相关
石峰[25] 慢性GVHD 患者外周血IL-10水平检测 IL-10水平与慢性GVHD发生负相关慢性GVHD患者IL-10血浆水平治疗中较治疗前后升高
Jung[26] 慢性GVHD 患者泪液细胞因子水平检测 IL-10与慢性GVHD（眼）严重程度正相关
Cocho[27] 慢性GVHD 患者泪液细胞因子水平检测 IL-10与慢性GVHD（眼）发生正相关
de Masson[28] 慢性GVHD 患者外周血单个核细胞检测 高产IL-10的CD24hiCD27+ B细胞和浆母细胞与慢性GVHD发生负相关
Peng[5] 慢性GVHD 患者单个核细胞分析 CD5+IL-10+ B细胞在慢性GVHD患者中增加（相较于非GVHD患者）；治疗中CD5+IL-10+ B细胞与慢性GVHD评分负相关
Miura[16] 自体GVHD 自体造血干细胞移植患者外周血IL-10-mRNA水平检测 IL-10 mRNA水平与GVHD发生正相关
1
李泊涵，陆芹，卞馨妮, 等. 单倍体造血干细胞移植对儿童重型再生障碍性贫血治疗的并发症分析[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(2):67-75.
2
Barnes DW, Loutit JF. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors[J]. Lancet (London, England), 1979, 2(8148):905-906.
3
Barnes DW, Loutit JF, Micklem HS. "Secondary disease" of radiation chimeras: a syndrome due to lymphoid aplasia[J]. Ann N Y Acad Sci, 1962, 99:374-385.
4
Billingham RE. The biology of graft-versus-host reactions[J]. Harvey lect, 1966-1967, 62:21-78.
5
Peng Y, Chen X, Liu Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10[J]. Leukemia, 2015, 29(3):636-646.
6
Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor[J]. Blood, 2005, 106(12):3995-4001.
7
Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease[J]. Hum Immunol, 2005, 66(6):700-710.
8
Noori-Daloii MR, Jalilian N, Izadi P, et al. Cytokine gene polymorphism and graft-versus-host disease: a survey in Iranian bone marrow transplanted patients[J]. Mol Biol Rep, 2013, 40(8):4861-4867.
9
Granero Farias M, Andrade dos Santos C, de Mello Vicente B, et al. The effects of gene polymorphisms on susceptibility to acute GVHD and survival of allogeneic HSCT recipients: IL-10 gene polymorphisms as a more accessible target to predict prognosis[J]. Hum Immunol, 2020, 81(1):18-25.
10
Cavet J, Dickinson AM, Norden J, et al. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation[J]. Blood, 2001, 98(5):1594-600.
11
蔡小矜，宋阿霞，王华, 等. 供、受者IL-10基因多态性对异基因造血干细胞移植疗效的影响[J]. 中华器官移植杂志, 2012, 33(12):732-736.
12
林嘉衍，王凯，高超，等. IL-10基因-592(C→A)位点单核苷酸多态性与儿童异基因造血干细胞移植后移植物抗宿主病的相关性研究[J]. 中国实验血液学杂志, 2019, 27(2):573-579.
13
Goussetis E, Varela I, Peristeri I, et al. Cytokine gene polymorphisms and graft-versus-host disease in children after matched sibling hematopoietic stem cell transplantation: a single-center experience[J]. Cell Mol Immunol, 2011, 8(3):276-280.
14
Takahashi H, Furukawa T, Hashimoto S, et al. Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2000, 26(12):1317-1323.
15
Kim DH, Lee NY, Sohn SK, et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation[J]. Transplantation, 2005, 79(11):1615-1622.
16
Miura Y, Thoburn CJ, Bright EC, et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD[J]. Blood, 2002, 100(7):2650-2658.
17
Hueso T, Coiteux V, Joncquel Chevalier Curt M, et al. Citrulline and monocyte-derived macrophage reactivity before conditioning predict acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2017, 23(6):913-921.
18
Sakata N, Yasui M, Okamura T, et al. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease[J]. Bone Marrow Transplant, 2001, 27(11):1153-1161.
19
Ju X, Wang J, Xu B, et al. Roles of interleukin-10 in acute graft-versus-host disease and graft rejection[J]. Chin Med J (Engl), 2003,116(4):534-537.
20
Ju XP, Xu B, Xiao ZP, et al. Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation[J]. Bone Marrow Transplantation, 2005, 35(12):1179-1186.
21
Fujii N, Hiraki A, Aoe K, et al. Serum cytokine concentrations and acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: concurrent measurement of ten cytokines and their respective ratios using cytometric bead array[J]. Int J Mol Med, 2006, 17(5):881-885.
22
Remberger M, Jaksch M, Uzunel M, et al. Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation[J]. Eur J Haematol, 2003, 70(6):384-391.
23
Weston LE, Geczy AF, Briscoe H. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD[J]. Bone Marrow Transplant, 2006, 37(2):207-212.
24
Körholz D, Kunst D, Hempel L, et al. Decreased interleukin 10 and increased interferon-γ production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation[J]. Bone Marrow Transplant, 1997, 19(7):691-695.
25
石峰，张圆圆，黄晓军. 白细胞介素-10在慢性移植物抗宿主病中的作用[J]. 现代中西医结合杂志, 2007, 16(16):2192-2193.
26
Jung JW, Han SJ, Song MK, et al. Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease[J]. Biol Blood Marrow Transplant, 2015, 21(12):2079-2085.
27
Cocho L, Fernández I, Calonge M, et al. Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model[J]. Invest Ophthalmol Vis Sci, 2016, 57(2):746-758.
28
de Masson A, Bouaziz JD, Le Buanec H, et al. CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease[J]. Blood, 2015, 125(11):1830-1839.
29
Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy[J]. Blood, 2018, 131(24):2651-2660.
30
Zhang P, Hill GR. Interleukin-10 mediated immune regulation after stem cell transplantation: Mechanisms and implications for therapeutic intervention[J]. Semin Immunol, 2019, 44:101322.
31
Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease[J]. Sci Transl Med, 2015, 7(308):308ra160.
32
Craciun LI, Stordeur P, Schandené L, et al. Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease[J]. Transplantation, 2002, 74(7):995-1000.
33
Di Renzo M, Sbano P, De Aloe G, et al. Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients[J]. Clin Exp Immunol, 2008, 151(3):407-413.
34
Toubai T, Malter C, Tawara I, et al. Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner[J]. Blood, 2010, 115(3):724-735.
35
Vanherwegen AS, Cook DP, Ferreira GB, et al. Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells[J]. J Steroid Biochem Mol Biol, 2019, 188:103-110.
36
Capitini CM, Davis JPE, Larabee SM, et al. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination[J]. Biol Blood Marrow Transplant, 2011, 17(6):790-799.
37
Chan YLT, Zuo J, Inman C, et al. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD[J]. Eur J Immunol, 2018, 48(2):316-329.
38
Kim HJ, Hwang SJ, Kim BK, et al. NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor beta, and by clonally deleting antigen-specific T cells[J]. Immunology, 2006, 118(1):101-111.
39
Perobelli SM, Mercadante ACT, Galvani RG, et al. G-CSF-induced suppressor IL-10+ neutrophils promote regulatory T cells that inhibit graft-versus-host disease in a long-lasting and specific way[J]. J Immunol, 2016, 197(9):3725-3734.
40
Leveson-Gower DB, Sega EI, Kalesnikoff J, et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells[J]. Blood, 2013, 122(22):3659-3665.
41
Sumitomo S, Nakachi S, Okamura T, et al. Identification of tonsillar CD4(+)CD25(-)LAG3(+) T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue[J]. J Autoimmun, 2017, 76:75-84.
42
Inoue M, Okamura T, Komai T, et al. CD4+CD25-LAG3+ regulatory T cells in humoral immunity[J]. Clin and Exp Neuroimmunol, 2019, 10(S1):4-11.
43
Wan J, Huang F, Hao S, et al. Interleukin-10 gene-modified dendritic cell-induced type 1 regulatory T cells induce transplant-tolerance and impede graft versus host disease after allogeneic stem cell transplantation[J]. Cell Physiol Biochem, 2017, 43(1):353-366.
44
Locafaro G, Andolfi G, Russo F, et al. IL-10-engineered human CD4(+) tr1 cells eliminate myeloid leukemia in an HLA class I-dependent mechanism[J]. Mol Ther, 2017, 25(10):2254-2269.
45
Yi J, Chen Z, Xu F, et al. IL-27 promotes human placenta-derived mesenchymal stromal cell ability to induce the generation of CD4(+)IL-10(+)IFN-γ(+) T cells via the JAK/STAT pathway in the treatment of experimental graft-versus-host disease[J]. J Immunol, 2019, 202(4):1124-1136.
46
Gutiérrez-Hoya A, López-Santiago R, Vela-Ojeda J, et al. Role of CD8 regulatory T cells versus Tc1 and Tc17 cells in the development of human graft-versus-host disease[J]. J Immunol Res, 2017, 2017: 1236219.
47
Pankratz S, Bittner S, Herrmann AM, et al. Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo[J]. FASEB J, 2014, 28(8):3435-3445.
48
Zhong H, Liu Y, Xu Z, et al. TGF-β-induced CD8(+)CD103(+) regulatory T cells show potent therapeutic effect on chronic graft-versus-host disease lupus by suppressing B cells[J]. Front Immunol, 2018, 9:35.
49
Tawara I, Sun Y, Liu C, et al. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease[J]. J Leukoc Biol, 2012, 91(4):667-675.
50
Sun M, Wu W, Chen L, et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis[J]. Nat Commun, 2018, 9(1):3555.
51
Ray A, Wang L, Dittel BN. IL-10-independent regulatory B-cell subsets and mechanisms of action[J]. Int Immunol, 2015, 27(10):531-536.
52
Le Huu D, Matsushita T, Jin G, et al. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease[J]. Blood, 2013, 121(16):3274-3283.
53
Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation[J]. Blood, 2006, 108(7):2485-2492.
54
Weber M, Stein P, Prüfer S, et al. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease[J]. Eur J Immunol, 2014, 44(6):1857-1865.
55
Khoder A, Sarvaria A, Alsuliman A, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD[J]. Blood, 2014, 124(13):2034-2045.
56
Min CK, Kim BG, Park G, et al. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2007, 39(10):637-645.
57
李宪哲，谢明颢，练磊. 间充质干细胞治疗炎症性肠病的应用及前景[J/CD]. 中华细胞与干细胞杂志(电子版), 2019, 9(4):236-241.
58
Wang L, Gu Z, Zhao X, et al. Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation[J]. Stem Cells Dev, 2016, 25(24):1874-1883.
59
Jitschin R, Mougiakakos D, Von Bahr L, et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation[J]. Stem cells (Dayton, Ohio), 2013, 31(8):1715-1725.
60
Hu LJ, Zhao XY, Yu XX, et al. Quantity and quality reconstitution of NKG2A+ natural killer cells are associated with graft-versus-host disease after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(1):1-11.
61
Wang X-N, Lange C, Schulz U, et al. Interleukin-10 modulation of alloreactivity and graft-versus-host reactions[J]. Transplantation, 2002, 74(6):772-778.
62
Smith SR, Terminelli C, Pennline KJ, et al. Inhibitory effects of recombinant human interleukin 10 on disease manifestations in a P-->F1 model of acute graft versus host disease[J]. Transplantation, 1995, 59(6):890-896.
63
Krenger W, Snyder K, Smith S, et al. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens[J]. Transplantation, 1994, 58(11):1251-1257.
64
Abraham S, Guo H, Choi JG, et al. Combination of IL-10 and IL-2 induces oligoclonal human CD4 T cell expansion during xenogeneic and allogeneic GVHD in humanized mice[J]. Heliyon, 2017, 3(4):e00276.
65
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease[J]. Transplantation, 1998, 66(9):1220-1229.
[1] 陈帅, 刘文宾, 吴迪炯, 俞庆宏, 陈均法, 庄海峰, 胡致平, 武利强, 郑智茵, 沈建平, 叶宝东. 改良FAC预处理方案在不同供者类型行异基因造血干细胞移植治疗再生障碍性贫血中的疗效分析[J]. 中华危重症医学杂志(电子版), 2022, 15(04): 296-299.
[2] 孔欣, 宋宝全, 刘吟, 张剑, 仇惠英, 吴德沛. 异基因造血干细胞移植并发难治性呃逆一例[J]. 中华移植杂志(电子版), 2023, 17(04): 253-255.
[3] 陈敏, 潘田中, 孙自敏. 祛铁治疗异基因造血干细胞移植术后三系植入不良一例[J]. 中华移植杂志(电子版), 2022, 16(03): 168-171.
[4] 赵晶, 丁淑怡, 周晓瑜, 章建丽, 许丽炜, 张力晨, 严佳丽, 程琼, 刘念, 金爱云. 异基因造血干细胞移植后并发慢性移植物抗宿主病患者生活质量变化及其影响因素分析[J]. 中华移植杂志(电子版), 2022, 16(03): 153-159.
[5] 刘恒, 吴涛. 伊布替尼治疗慢性移植物抗宿主病的研究进展[J]. 中华移植杂志(电子版), 2021, 15(05): 317-320.
[6] 刘妍, 吴涛, 毛东锋, 鱼玲玲, 白海. 人类白细胞抗原全相合异基因造血干细胞移植治疗多基因突变难治性急性髓系白血病一例[J]. 中华移植杂志(电子版), 2021, 15(04): 229-231.
[7] 朱伟芳, 方红. 联合窄波紫外线治疗皮肤扁平苔藓样慢性移植物抗宿主病一例[J]. 中华移植杂志(电子版), 2021, 15(03): 169-171.
[8] 张超琅, 郭晓萍, 赵芬英, 徐晓军. 婴幼儿异基因造血干细胞移植后腹泻伴胰腺再生蛋白3α升高二例[J]. 中华移植杂志(电子版), 2021, 15(02): 116-118.
[9] 张宁, 周明明, 蒋正英, 吴桂新, 吕奇坤. 肺癌合并脓毒症mHLA-DR、CD39+Treg及IL-10表达与预后相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 169-174.
[10] 洪宇泽, 郑利平, 刘飞, 江晨. 血清Th2型细胞因子IL-6、IL-10评估社区获得性肺炎病情及预后意义[J]. 中华肺部疾病杂志(电子版), 2021, 14(03): 318-320.
[11] 刘文慧, 吴涛, 张曦. 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 242-246.
[12] 李芸芸, 吴涛, 毛东锋, 鱼玲玲, 刘文慧. 轻型β-地中海贫血供者异基因造血干细胞移植治疗重型再生障碍性贫血1例[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 84-86.
[13] 苏春艳, 吴涛, 毛东锋, 刘文慧, 鱼玲玲, 白海. 异基因造血干细胞移植治疗急性混合细胞白血病后继发外周T细胞淋巴瘤1例[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(05): 289-292.
[14] 韦远, 徐西占, 梁庆丰. 免疫性眼表疾病眼表菌群的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 55-59.
[15] 赵洁, 王岚, 杨红枚, 何屹, 袁红. 异基因造血干细胞移植后并发自身免疫性溶血性贫血患者产生类抗体血清学检测方法及输血策略[J]. 中华临床医师杂志(电子版), 2022, 16(05): 452-456.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号